



Nam Quoc Bui

Clinical Assistant Professor, Medicine - Oncology

CLINICAL OFFICES

875 Blake Wilbur Dr

Stanford, CA 94305

Tel (650) 724-5214

Fax (650) 724-3556

Bio

BIO

Dr. Bui is a Clinical Assistant Professor of Medicine at the Stanford Cancer Institute and a specialist in the Sarcoma and Developmental Therapeutics programs. Dr. Bui earned an undergraduate degree in Computer Science at Stanford University and went on to earn his medical degree from the University of Texas Southwestern Medical Center. He completed Internal Medicine residency at Stanford Hospital and Hematology/Oncology fellowship at the University of California San Diego, where he performed extensive research in bioinformatics to analyze tumor sequencing data. His research background and interests are in the field of bioinformatics as applied to large data sets and the study of novel compounds in rare malignancies.

CLINICAL FOCUS

- Internal Medicine
- Medical Oncology
- Sarcoma
- Phase 1 Trials

ACADEMIC APPOINTMENTS

- Clinical Assistant Professor, Medicine - Oncology
- Member, Stanford Cancer Institute

BOARDS, ADVISORY COMMITTEES, PROFESSIONAL ORGANIZATIONS

- Member, American Society of Clinical Oncology (ASCO) (2014 - present)
- Associate Member, Stanford Cancer Institute (2018 - present)
- Member, Connective Tissue Oncology Society (CTOS) (2017 - present)

PROFESSIONAL EDUCATION

- Residency: Stanford University Internal Medicine Residency (2014) CA
- Board Certification: Medical Oncology, American Board of Internal Medicine (2017)
- Fellowship: UCSD Hematology and Oncology Training (2017) CA
- Board Certification: Hematology, American Board of Internal Medicine (2017)

- Medical Education: University of Texas Southwestern Medical School Registrar (2011) TX
- Board Certification: Internal Medicine, American Board of Internal Medicine (2014)
- B.S., Stanford University , Computer Science (2007)

LINKS

- Get a Second Opinion: <https://stanfordhealthcare.org/second-opinion/overview.html>

Research & Scholarship

CLINICAL TRIALS

- ADI-PEG 20 in Combination With Gemcitabine and Docetaxel for the Treatment of Soft Tissue Sarcoma, Recruiting
- Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations, Recruiting
- Olaparib and Temozolomide in Treating Patients With Advanced, Metastatic, or Unresectable Uterine Leiomyosarcoma, Not Recruiting

Publications

PUBLICATIONS

- **Increasing Clinical Trial Accrual via Automated Matching of Biomarker Criteria.** *Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing*
Chen, J. W., Kunder, C. A., Bui, N., Zehnder, J. L., Costa, H. A., Stehr, H.
2020; 25: 31–42
- **Dose escalation of tinostamustine in patients with advanced solid tumors**
Mita, A., Loeffler, M., Bui, N., Mehrling, T., Rimmel, B. J., Natale, R. B., Kummar, S.
AMER ASSOC CANCER RESEARCH.2019
- **Multi-institutional analysis of outcomes in patients with dedifferentiated chondrosarcoma (DDCS).**
Bui, N., Dietz, H., Hirbe, A. C., Ganjoo, K. N., Van Tine, B., Keedy, V., Davis, E. J.
AMER SOC CLINICAL ONCOLOGY.2019
- **A phase II study of ADI-PEG 20 in combination with gemcitabine and docetaxel for the treatment of soft tissue sarcoma.**
Van Tine, B., Bui, N., Prudner, B., Bomalaski, J. S., Wu, B., Chawla, S. P., Ganjoo, K. N., Oppelt, P., Hirbe, A. C.
AMER SOC CLINICAL ONCOLOGY.2019
- **Chromatin dysregulation and DNA methylation at transcription start sites associated with transcriptional repression in cancers** *NATURE COMMUNICATIONS*
Ando, M., Saito, Y., Xu, G., Bui, N. Q., Medetgul-Ernar, K., Pu, M., Fisch, K., Ren, S., Sakai, A., Fukusumi, T., Liu, C., Haft, S., Pang, et al
2019; 10
- **Next-Generation Sequencing of Tissue and Circulating Tumor DNA: The UC San Diego Moores Center for Personalized Cancer Therapy Experience with Breast Malignancies** *MOLECULAR CANCER THERAPEUTICS*
Shatsky, R., Parker, B. A., Bui, N. Q., Heisten, T., Schwab, R. B., Boles, S. G., Kurzrock, R.
2019; 18 (5): 1001–11
- **Contemporary management of metastatic soft tissue sarcoma.** *Current problems in cancer*
Bui, N. Q., Wang, D. S., Hiniker, S. M.
2019
- **Editorial.** *Current problems in cancer*
Bui, N.
2019; 43 (4): 249
- **A clinico-genomic analysis of soft tissue sarcoma patients reveals CDKN2A deletion as a biomarker for poor prognosis.** *Clinical sarcoma research*
Bui, N. Q., Przybyl, J., Trabucco, S. E., Frampton, G., Hastie, T., van de Rijn, M., Ganjoo, K. N.
2019; 9: 12

- **Reviewing the role of healthy volunteer studies in drug development.** *Journal of translational medicine*
Karakunnel, J. J., Bui, N., Palaniappan, L., Schmidt, K. T., Mahaffey, K. W., Morrison, B., Figg, W. D., Kummar, S.
2018; 16 (1): 336
- **Disruption of NSD1 in head and neck cancer promotes favorable chemotherapeutic responses linked to hypomethylation.** *Molecular cancer therapeutics*
Bui, N., Huang, J. K., Bojorquez-Gomez, A., Licon, K., Sanchez, K. S., Tang, S. N., Beckett, A. N., Wang, T., Zhang, W., Shen, J. P., Kreisberg, J. F., Ideker, T.
2018
- **A multicenter phase II study of Q3 week or weekly paclitaxel in combination with bevacizumab for the treatment of metastatic or unresectable angiosarcoma.** *Rare tumors*
Bui, N., Kamat, N., Ravi, V., Chawla, S., Lohman, M., Ganjoo, K. N.
2018; 10: 2036361318771771
- **Cell-Free DNA from Ascites and Pleural Effusions: Molecular Insights into Genomic Aberrations and Disease Biology** *MOLECULAR CANCER THERAPEUTICS*
Husain, H., Nykin, D., Nam Bui, N., Quan, D., Gomez, G., Woodward, B., Venkatapathy, S., Dutttagupta, R., Fung, E., Lippman, S. M., Kurzrock, R.
2017; 16 (5): 948-955
- **Strategies to Overcome Bypass Mechanisms Mediating Clinical Resistance to EGFR Tyrosine Kinase Inhibition in Lung Cancer** *MOLECULAR CANCER THERAPEUTICS*
Husain, H., Scur, M., Murtuza, A., Bui, N., Woodward, B., Kurzrock, R.
2017; 16 (2): 265-272
- **Molecular insights into desmoid tumors.** *Oncotarget*
Bui, N., Kummar, S.
2017; 8 (53): 90608–9
- **Chart review versus an automated bioinformatic approach to assess real-world crizotinib effectiveness in ALK-positive NSCLC.** *JCO clinical cancer informatics*
Bui, N., Henry, S., Wood, D., Wakelee, H. A., Neal, J. W.
2017; 2017
- **Evolution of early phase clinical trials in oncology.** *Journal of molecular medicine (Berlin, Germany)*
Bui, N. Q., Kummar, S.
2017
- **Novel Treatment Strategies for Brain Metastases in Non-small-cell Lung Cancer** *CURRENT TREATMENT OPTIONS IN ONCOLOGY*
Bui, N., Woodward, B., Johnson, A., Husain, H.
2016; 17 (5)
- **Reactivation of hepatitis B virus after withdrawal of erlotinib** *CURRENT ONCOLOGY*
Bui, N., Wong-Sefidan, I.
2015; 22 (6): 430-432
- **Dorsal aesthetic lines in rhinoplasty: a quantitative outcome-based assessment of the component dorsal reduction technique.** *Plastic and reconstructive surgery*
Mojallal, A., Ouyang, D., Saint-Cyr, M., Bui, N., Brown, S. A., Rohrich, R. J.
2011; 128 (1): 280-288